Bromodiphenhydramine
Ambenyl, Ambodryl, Bromanyl (bromodiphenhydramine) is a small molecule pharmaceutical. Bromodiphenhydramine was first approved as Ambodryl on 1982-01-01. It is used to treat allergic rhinitis perennial, anxiety disorders, cough, motion sickness, and nausea amongst others in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| allergic rhinitis perennial | EFO_1001417 | D012221 | J30.89 |
| anxiety disorders | EFO_0006788 | D001008 | F41.1 |
| cough | HP_0012735 | D003371 | R05 |
| motion sickness | — | D009041 | T75.3 |
| nausea | HP_0002018 | D009325 | R11.0 |
| parkinson disease | EFO_0002508 | D010300 | G20 |
| sleep initiation and maintenance disorders | — | D007319 | F51.01 |
| urticaria | EFO_0005531 | D014581 | L50 |
| vertigo | — | D014717 | H81.39 |
| vomiting | HP_0002013 | D014839 | R11.1 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
38 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | — | 2 | 2 | — | 5 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | — | 2 | 2 | — | 4 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | 1 | 1 | — | 2 |
| Glucose intolerance | D018149 | HP_0000833 | R73.03 | — | — | — | 1 | — | 1 |
| Diabetic neuropathies | D003929 | EFO_1000783 | — | — | — | 1 | — | 1 | |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | 1 | — | 1 |
| Hyperaldosteronism | D006929 | HP_0011736 | E26 | — | — | — | 1 | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ovarian hyperstimulation syndrome | D016471 | — | 2 | — | — | — | 2 | ||
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 1 | — | — | 1 | 2 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | 1 | — | — | — | 1 |
| Ischemic stroke | D000083242 | 1 | 1 | — | — | — | 1 | ||
| Traumatic brain injuries | D000070642 | S06 | 1 | 1 | — | — | — | 1 | |
| Cerebral hemorrhage | D002543 | 1 | 1 | — | — | — | 1 | ||
| Subarachnoid hemorrhage | D013345 | EFO_0000713 | I60 | 1 | 1 | — | — | — | 1 |
| Subdural hematoma | D006408 | HP_0100309 | 1 | 1 | — | — | — | 1 | |
| Fever | D005334 | HP_0001945 | R50.9 | 1 | 1 | — | — | — | 1 |
| Intellectual disability | D008607 | F73 | — | 1 | — | — | — | 1 |
Show 3 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anorexia nervosa | D000856 | EFO_0004215 | F50.0 | 1 | — | — | — | — | 1 |
| Adenomyosis | D062788 | EFO_1001757 | N80.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic pain | D059350 | HP_0012532 | — | — | — | — | 1 | 1 | |
| Fibromyalgia | D005356 | EFO_0005687 | M79.1 | — | — | — | — | 1 | 1 |
| Parkinsonian disorders | D020734 | HP_0001300 | — | — | — | — | 1 | 1 | |
| Graves ophthalmopathy | D049970 | EFO_1001466 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | BROMODIPHENHYDRAMINE |
| INN | bromazine |
| Description | Bromazine is a tertiary amino compound that is the 4-bromobenzhydryl ether of 2-(dimethylamino)ethanol. An antihistamine with antimicrobial properties, it is used in the control of cutaneous allergies. It has a role as an antimicrobial agent, a muscarinic antagonist and a H1-receptor antagonist. It is a tertiary amino compound and an organobromine compound. It contains a bromazine hydrochloride. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CN(C)CCOC(c1ccccc1)c1ccc(Br)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 118-23-0 |
| RxCUI | 19759 |
| ChEMBL ID | CHEMBL1201245 |
| ChEBI ID | 59177 |
| PubChem CID | 2444 |
| DrugBank | DB01237 |
| UNII ID | T032BI7727 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 40 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,618 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more